var data={"title":"Potassium iodide and iodine (Lugol solution): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium iodide and iodine (Lugol solution): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/43941?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-iodide-and-iodine-lugol-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium iodide and iodine (Lugol solution): Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=potassium-iodide-and-iodine-lugol-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium iodide and iodine (Lugol solution): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802367\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiseptic, Topical;</li>\n      <li>\n        Antithyroid Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802397\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antiseptic:</b> Topical: Apply directly to area(s) requiring antiseptic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroidectomy preparation  (off-label use):</b> Oral: 5 to 7 drops (0.25 to 0.35 mL) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid gland protection during radiopharmaceutical use (off-label use):</b> Oral: 20 drops 3 times daily has been recommended (Bexxar prescribing information 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Initiate 1 to 48 hours prior to radiopharmaceutical exposure and continue after radiopharmaceutical administration until risk of exposure has diminished (treatment initiation time and duration is dependent on the radiopharmaceutical agent used, consult specific protocol or labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxic crisis/thyroid storm (off-label use):</b> Oral: 4 to 8 drops every 6 to 8 hours; initiate therapy at least 1 hour following the initial dose of antithyroid drug therapy (eg, propylthiouracil, methimazole) (Nayak 2006; Ross 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802396\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=potassium-iodide-and-iodine-lugol-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium iodide and iodine (Lugol solution): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Thyrotoxic crisis (off-label use):</b> Oral: 4 to 8 drops 3 times daily; initiate therapy preferably 2 hours following the initial dose of antithyroid drug therapy (eg, propylthiouracil, methimazole) (Eyal 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803629\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448476\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448477\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802404\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Potassium iodide 10% and iodine 5% (8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Potassium iodide 10% and iodine 5% (14 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tincture, External:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Potassium iodide 5% and iodine 7% (30 mL, 480 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802365\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16350658\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Apply topically directly to area(s) requiring antiseptic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Has also been used orally (off-label route).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802370\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Antiseptic: </b>Topical antiseptic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744678\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Thyroidectomy preparation; Thyroid gland protection during radiopharmaceutical use; Thyrotoxic crisis/thyroid storm (adults); Thyrotoxic crisis/thyroid storm (children); Block thyroidal uptake of radioactive isotopes of iodine in a radiation emergency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802787\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Potassium iodide and iodine (Strong Iodide Solution or Lugol's solution) may be confused with potassium iodide products, including saturated solution of potassium iodide (SSKI&reg;)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dosage volume: Dosing errors have been reported during the prescribing, dispensing, and administration of potassium iodide-containing solutions (eg, Lugol&rsquo;s, SSKI). Errors have occurred when <b>mL</b> doses were administered, when only <b>drops</b> were indicated for the dose. Carefully review dosage and administration information; appropriate oral dosage is most commonly expressed as drops to provide  doses less than 1 mL. Dispensing unit doses is also highly recommended; pharmacists should never dispense quantities that could be lethal if consumed as a single dose. (ISMP, 2011).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802379\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, myxedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, fatigue, metallic taste, numbness, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Goiter, hyperthyroidism, hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, nausea, salivary gland disease (tenderness), stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Adenopathy, thyroid adenoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngeal edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug overdose (with prolonged treatment/high doses), fever, iodism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802375\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iodine or any component of the formulation; active tuberculosis; dermatitis herpetiformis; hypocomplementemic vasculitis; nodular thyroid disease with heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802376\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypothyroidism: Prolonged use can lead to hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Can cause acne flare-ups and/or dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenal insufficiency: Use with caution in patients with Addison's disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchitis: Use with caution in patients with acute bronchitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac disease: Use with caution in patients with cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myotonia congenita: Use with caution in patients with myotonia congenita.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Use with caution in patients with a history of hyperthyroidism; use is contraindicated in nodular thyroid conditions with heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tuberculosis: Use with caution in patients with tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299923\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802385\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9455&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802371\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">D (potassium iodide) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802372\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration. Repeat dosing should be avoided if possible. Refer to Iodine for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802374\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Skin rash in the nursing infant has been reported with maternal intake of potassium iodide. Refer to Iodine monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802398\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Thyroid function tests, signs/symptoms of hyperthyroidism; thyroid function should be monitored in pregnant women, neonates, and young infants if repeat doses are required following radioactive iodine exposure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802391\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">In hyperthyroidism, iodine temporarily inhibits thyroid hormone synthesis and secretion into the circulation; use also decreases thyroid gland  size and vascularity. Serum T<sub>4</sub>  and T<sub>3</sub> concentrations can be reduced for several weeks with use but effect will not be maintained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Following radioactive iodine exposure, potassium iodide blocks uptake of radioiodine by the thyroid, reducing the risk of thyroid cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802393\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Onset of action: Hyperthyroidism: 24-48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Peak effect: 10-15 days after continuous therapy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50470378\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gemstain (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Eyal.2008\"></a>Eyal O and Rose SR, &ldquo;Thyroid Disease,&rdquo; in <i>Roger&rsquo;s Textbook of Pediatric Intensive Care</i>, 4th ed, David G Nichols, ed, Philadelphia, PA: Lippincott, Williams, &amp; Wilkins, 2008; p. 1658.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giammarile F, Chiti A, Lassmann M, Brans B, Flux G; EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. <i>Eur J Nucl Med Mol Imaging</i>. 2008;35(5):1039-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/18274745/pubmed\" target=\"_blank\" id=\"18274745\">18274745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &ldquo;Look out for Lugol&rsquo;s...Error-prevention strategies for this strong iodine solution,&rdquo; ISMP Medication Safety Alert, December 1, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17127140\"></a>Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo; <i>Endocrinol Metab Clin North Am</i>, 2006, 35(4):663-86, vii.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/17127140/pubmed\" target=\"_blank\" id=\"17127140\">17127140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-and-iodine-lugol-solution-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9455 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F802367\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F802397\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F802396\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F803629\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448476\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448477\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F802404\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F802365\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16350658\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F802370\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744678\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F802787\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F802379\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F802375\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F802376\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299923\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F802385\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F802371\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F802372\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F802374\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F802398\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F802391\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F802393\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50470378\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9455|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-iodide-and-iodine-lugol-solution-patient-drug-information\" class=\"drug drug_patient\">Potassium iodide and iodine (Lugol solution): Patient drug information</a></li><li><a href=\"topic.htm?path=potassium-iodide-and-iodine-lugol-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">Potassium iodide and iodine (Lugol solution): Pediatric drug information</a></li></ul></div></div>","javascript":null}